StreetInsider.com News Articles

Avalyn to Participate in the Jefferies Global Healthcare Conference

Wed, 27 May 2026 08:00:00 -0400

BOSTON, May 27, 2026 (GLOBE NEWSWIRE) -- Avalyn Pharma Inc. (Nasdaq: AVLN), a clinical-stage biopharmaceutical company pioneering inhaled therapies to transform the treatment paradigm of serious, rare respiratory diseases, today announced Avalyn management will present a company overview at the Jefferies Global Healthcare Conference in New York City on June 4, 2026, at 9:55-10:25 a.m. ET.

Access to the live webcast of this event, and the archived recording, will be posted under the News & Events page of the Investor section of the company’s website at https://investors.avalynpharma.com/

About Avalyn Pharma
Avalyn aims to

Avalyn to Participate in the Jefferies Global Healthcare Conference

Wed, 27 May 2026 08:00:00 -0400

About Avalyn Pharma
Avalyn aims to

Evercore ISI Starts Avalyn Pharma (AVLN) at Outperform

Tue, 26 May 2026 07:41:03 -0400

Evercore ISI analyst Gavin Clark-Gartner initiates coverage on Avalyn Pharma (NASDAQ: AVLN) with a Outperform rating.

For an analyst ratings summary and ratings history on Avalyn Pharma click here. For more ratings news on Avalyn Pharma click here.

Shares of Avalyn Pharma closed at $28.84 yesterday.

Morgan Stanley Starts Avalyn Pharma (AVLN) at Overweight

Tue, 26 May 2026 00:54:55 -0400

Morgan Stanley analyst Judah Frommer initiates coverage on Avalyn Pharma (NASDAQ: AVLN) with a Overweight rating and a price target of $53.00.

The analyst comments: “AVLN is a clinical-stage biotech company developing AP01 and AP02, inhaled formulations of pirfenidone (branded as Esbriet) and nintedanib (branded as Ofev), respectively. Esbriet and Ofev were the first two anti-fibrotic therapies approved for pulmonary fibrosis (PF) and both have achieved blockbuster status. However, despite the poor prognosis facing PF patients (median survival of ~3 to 5 years), the uptake of these anti-fibrotics has been significantly limited by their challenging safety/tolerability profiles that likely stem from

Morgan Stanley Starts Avalyn Pharma (AVLN) at Overweight

Tue, 26 May 2026 00:54:55 -0400

Morgan Stanley analyst Judah Frommer initiates coverage on Avalyn Pharma (NASDAQ: AVLN) with a Overweight rating and a price target of $53.00.

Jefferies Starts Avalyn Pharma (AVLN) at Buy

Mon, 25 May 2026 10:31:59 -0400

Jefferies analyst Roger Song initiates coverage on Avalyn Pharma (NASDAQ: AVLN) with a Buy rating and a price target of $52.00.

The analyst comments: “The Investment Case in Three Arguments

1. The ATLAS efficacy signal is real and multi-stream. AP01 100mg BID showed -0.4%/yr FVC vs. -4.9%/yr at 50mg QD and ~-6 to -8%/yr natural history yielding a total 83% reduction (p=0.041). Three independent streams of efficacy: 1) FVC slope, 2) qHRCT structural improvement (3 super-responders: +380/+500/+850mL), and 3) KBILD PRO. DSMB unanimously switched all patients to 100mg BID on interim review. With 23/100 OLE pts still on drug for 4.5yrs+, PPF-naive

Jefferies Starts Avalyn Pharma (AVLN) at Buy

Mon, 25 May 2026 10:31:59 -0400

Jefferies analyst Roger Song initiates coverage on Avalyn Pharma (NASDAQ: AVLN) with a Buy rating and a price target of $52.00.

The analyst comments: “The Investment Case in Three Arguments

Guggenheim Starts Avalyn Pharma (AVLN) at Buy

Mon, 25 May 2026 10:13:02 -0400

Guggenheim analyst Seamus Fernandez initiates coverage on Avalyn Pharma (NASDAQ: AVLN) with a Buy rating and a price target of $80.00.

The analyst comments: “We are initiating coverage of Avalyn Pharma (AVLN) with a BUY rating and $80/share price target based on our high conviction in multi-blockbuster sales for AVLN's inhaled antifibrotics for idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF), which combined currently represent ~300,000 patients with dismal prognoses. Our expert checks and pulmonary fibrosis survey (n=50) highlight the serious unmet need in IPF/PPF despite approved and new therapies available, as well as high confidence that Avalyn's pipeline has

Guggenheim Starts Avalyn Pharma (AVLN) at Buy

Mon, 25 May 2026 10:13:02 -0400

Guggenheim analyst Seamus Fernandez initiates coverage on Avalyn Pharma (NASDAQ: AVLN) with a Buy rating and a price target of $80.00.

Avalyn to present 4-year data on inhaled pirfenidone at EULAR 2026

Thu, 21 May 2026 08:03:39 -0400

Avalyn Pharma Inc. (NASDAQ: AVLN) announced it will present updated findings from its ATLAS open-label extension trial at the European Alliance of Associations for Rheumatology conference scheduled for June 3-6, 2026, in London.

The poster presentation will highlight long-term tolerability data for AP01, the company's inhaled pirfenidone treatment, in patients with progressive pulmonary fibrosis who received up to four years of treatment. The session is scheduled for Saturday, June 6, at 10:15 BST.

The presentation, titled "Nebulized pirfenidone (AP01) for progressive pulmonary fibrosis in connective tissue disease-associated and other interstitial lung diseases: 4-year data from the ATLAS open label extension trial," will

Avalyn Announces Additional Long-term Data on AP01, Inhaled Pirfenidone, for the Treatment of Pulmonary Fibrosis to be Presented at the European Alliance of Associations for Rheumatology 2026

Thu, 21 May 2026 08:00:00 -0400

BOSTON, May 21, 2026 (GLOBE NEWSWIRE) -- Avalyn Pharma Inc. (Nasdaq: AVLN), a clinical-stage biopharmaceutical company pioneering inhaled therapies to transform the treatment paradigm of serious, rare respiratory diseases, today announced an upcoming poster presentation at the European Alliance of Associations for Rheumatology (EULAR) 2026, being held June 3-6, 2026, in London, England.

Updated findings from the ATLAS open-label extension trial will highlight the long-term tolerability profile of AP01 (inhaled pirfenidone) among the cohort of patients with progressive pulmonary fibrosis at up to four years of treatment. See the EULAR online program for

Avalyn Announces Additional Long-term Data on AP01, Inhaled Pirfenidone, for the Treatment of Pulmonary Fibrosis to be Presented at the European Alliance of Associations for Rheumatology 2026

Thu, 21 May 2026 08:00:00 -0400

Form SCHEDULE 13D Avalyn Pharma Inc. Filed by: SUVRETTA CAPITAL MANAGEMENT, LLC

Fri, 08 May 2026 18:52:00 -0400

si-local-file:///var/storage/secattach/20260508/26462919.html

Form SCHEDULE 13D Avalyn Pharma Inc. Filed by: SR ONE CAPITAL MANAGEMENT, LLC

Fri, 08 May 2026 16:42:00 -0400

si-local-file:///var/storage/secattach/20260508/26461945.html

Form SCHEDULE 13G Avalyn Pharma Inc. Filed by: PERCEPTIVE ADVISORS LLC

Thu, 07 May 2026 16:17:00 -0400

si-local-file:///var/storage/secattach/20260507/26453729.html

Form 4 Avalyn Pharma Inc. For: May 01 Filed by: Novo Holdings A/S

Tue, 05 May 2026 16:15:00 -0400

si-local-file:///var/storage/secattach/20260505/26435006.html

Avalyn to Present Patient-Centered Research on AP01 Delivery and Supportive Care Experiences at American Thoracic Society 2026 International Conference

Tue, 05 May 2026 16:01:00 -0400

BOSTON, May 05, 2026 (GLOBE NEWSWIRE) -- Avalyn Pharma Inc. (Nasdaq: AVLN), a clinical-stage biopharmaceutical company pioneering inhaled therapies to transform the treatment paradigm of serious, rare respiratory diseases, today announced two presentations at the American Thoracic Society (ATS) 2026 International Conference being held May 15-20, 2026, in Orlando, FL.

“Our presentations at ATS reflect a core belief at Avalyn - that patients should help shape the therapies designed to serve them,” said Lyn Baranowski, CEO of Avalyn Pharma. “By focusing on inhaled approaches and integrating patient and caregiver input early in development, we aim

Avalyn to Present Patient-Centered Research on AP01 Delivery and Supportive Care Experiences at American Thoracic Society 2026 International Conference

Tue, 05 May 2026 16:01:00 -0400

Form SCHEDULE 13G Avalyn Pharma Inc. Filed by: FMR LLC

Tue, 05 May 2026 10:07:00 -0400

si-local-file:///var/storage/secattach/20260505/26431788.html

Form 4 Avalyn Pharma Inc. For: May 01 Filed by: FMR LLC

Tue, 05 May 2026 08:38:00 -0400

si-local-file:///var/storage/secattach/20260505/26430680.html

Form 4 Avalyn Pharma Inc. For: Apr 29 Filed by: Golden Adam H.

Mon, 04 May 2026 06:06:00 -0400

si-local-file:///var/storage/secattach/20260504/26420427.html

Two River and Vida Ventures Extend Track Record of Company Creation and Value Realization Following the Candid Therapeutics’ Acquisition by UCB

Sun, 03 May 2026 20:00:00 -0400

LOS ANGELES, BOSTON & NEW YORK--(BUSINESS WIRE)-- Two River, LLC (“Two River”) and Vida Ventures (“Vida”), both part of the Bellco Health ecosystem, today acknowledged the announced acquisition of Candid Therapeutics (“Candid”), a privately held clinical-stage biotechnology company redefining the treatment of autoimmune and inflammatory diseases through novel T-cell engagers (TCEs), by UCB (Euronext: UCB), a global biopharmaceutical company, for up to $2.2 billion, including $2.0 billion upfront.

Two River and Vida played central roles in the creation and early development of Candid. Two River, together with Third Rock Ventures, helped found Candid, continuing Two River’s consistent track

Two River and Vida Ventures Extend Track Record of Company Creation and Value Realization Following the Candid Therapeutics’ Acquisition by UCB

Sun, 03 May 2026 20:00:00 -0400

Two River and Vida played central roles in the creation and early development of Candid. Two River, together with Third Rock Ventures, helped found Candid, continuing Two River’s consistent track

Two River and Vida Ventures Extend Track Record of Company Creation and Value Realization Following the Candid Therapeutics’ Acquisition by UCB

Sun, 03 May 2026 20:00:00 -0400

Two River and Vida played central roles in the creation and early development of Candid. Two River, together with Third Rock Ventures, helped found Candid, continuing Two River’s consistent track

Two River and Vida Ventures Extend Track Record of Company Creation and Value Realization Following the Candid Therapeutics’ Acquisition by UCB

Sun, 03 May 2026 20:00:00 -0400

Two River and Vida played central roles in the creation and early development of Candid. Two River, together with Third Rock Ventures, helped found Candid, continuing Two River’s consistent track